港交所(00388.HK)擬於今年第三季度推出投資服務通(IR Connect)
港交所(00388.HK)宣布,擬於今年第三季度推出全新的投資者關係網絡平台投資服務通(IR Connect),以增進香港的上市公司與投資者之間的聯繫與溝通,幫助在港交所上市的公司與本地及全球投資者和分析師建立聯繫。
投資服務通將分階段推出,在2022年第三季度上線時,該平台將向上市公司免費提供股東持股情況、市場行情、相關股票關鍵財務指標及研究評級等查詢功能,向公眾免費提供上市公司簡介及股票行情等查詢功能。更多上市公司與投資者之間的互動功能將在後期陸續提供。
在推出投資者服務通之前,港交所還將在今年舉辦一系列走近上市企業活動,以促進上市公司與投資者之間的溝通和互動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.